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Abstract 
Background and purpose: Benzofurans are newly used psychoactive substances, but their 
pharmacology is unknown. The aim of the present study was to pharmacologically 
characterize benzofurans in vitro. 
Experimental approach: We assessed the effects of the benzofurans 5-APB, 5-APDB, 6-
APB, 6-APDB, 4-APB, 7-APB, 5-EAPB, and 5-MAPDB and benzodifuran 2C-B-FLY on the 
human noradrenaline (NA), dopamine (DA), and serotonin (5-HT) uptake transporters using 
HEK 293 cells that express the respective transporters. We also investigated the release of 
NA, DA, and 5-HT from monoamine-preloaded cells, monoamine receptor binding affinity, 
and 5-HT2A and 5-HT2B receptor activation. 
Key results: All of the benzofurans inhibited NA and 5-HT uptake more than DA uptake, 
similar to methylenedioxymethamphetamine (MDMA) and unlike methamphetamine. All of 
the benzofurans also released monoamines and interacted with trace amine-associated 
receptor 1 (TAAR1), similar to classic amphetamines. Most benzofurans were partial 5-HT2A 
agonists similar to MDMA, but also 5-HT2B receptor agonists, unlike MDMA and 
methamphetamine. The benzodifuran 2C-B-FLY very potently interacted with 5-HT2 
receptors and also bound to TAAR1. 
Conclusions and implications: Despite very similar structures, differences were found in 
the pharmacological profiles of the different benzofurans and compared with their 
amphetamine analogues. Benzofurans acted as indirect monoamine agonists that interact 
with transporters similarly to MDMA. The benzofurans also interacted with serotonergic 
receptors. This pharmacological profile likely results in MDMA-like entactogenic 
psychoactive properties. However, benzofurans produce 5-HT2B receptor activation 
associated with heart valve fibrosis. The pharmacology of 2C-B-FLY indicates predominant 
hallucinogenic properties and a risk for vasoconstriction. 
 
Keywords: Novel psychoactive substances, benzofuran, pharmacology, monoamine 
transporter, receptor 
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Abbreviations: 5-APB, 5-(2-aminopropyl)benzofuran; 6-APB, 6-(2-aminopropyl)benzofuran; 
5-APDB, 5-(2-aminopropyl)-2,3-dihydrobenzofuran; 6-APDB, 6-(2-aminopropyl)-2,3-
dihydrobenzofuran; 4-APB, 4-(2-aminopropyl)benzofuran; 7-APB, 7-(2-
aminopropyl)benzofuran; bromo-dragonFLY, 1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-
aminoprop-ane; β-keto-MDA, β-keto-3,4-methylenedioxyamphetamine; 2C-B-fly, 8-bromo-
2,3,6,7-benzo-dihydro-difuran-ethylamine; DA, dopamine; DAT, DA transporter; 5-EAPB, 5-
(2-ethylaminopropyl)benzofuran; 5-HT, 5-hydroxytryptamine or serotonin; 5-MAPDB, 1-(2,3-
dihydrobenzofuran-5-yl)-N-methylpropan-2-amine; MDMA, 3,4-
methylenedioxymethamphetamine; MDA, 3,4-methylenedioxyamphetamine; NA, 
noradrenaline; NET, noradrenaline transporter; SERT, serotonin transporter; TAAR, trace 
amine-associated receptor. 
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Introduction 
Novel psychoactive substances are newly used designer drugs (“internet drugs,” “research 
chemicals,” “legal highs”) that potentially pose similar health risks to classic illicit substances. 
In recent years, the number of newly detected psychoactive substances on the illicit drug 
market has dramatically increased. In the European Union, 41 novel psychoactive 
substances were identified for the first time in 2010, 49 were identified in 2011, 73 were 
identified in 2012, and 81 were identified in 2013 within the European Early Warning System 
(EMCDDA, 2014). 
Benzofurans are a group of novel psychoactive substances (King, 2014) of particular 
interest because they are structurally very similar to the popular recreational drug 3,4-
methylenedioxymethamphetamine (MDMA) and its active metabolite 3,4-
methylenedioxyamphetamine (MDA; (Greene, 2013). 5-(2-Aminopropyl)benzofuran (5-APB) 
and 6-(2-aminopropyl)benzofuran )(-APB) are benzofuran analogues of MDA (Fig. 1). 5-(2-
Aminopropyl)-2,3-dihydrobenzofuran (5-APDB) and 6-(2-aminopropyl)-2,3-
dihydrobenzofuran (6-APDB) are dihydrobenzofuran analogues (Fig. 1) that were originally 
synthesized for research purposes (Monte et al., 1993). 4-(2-Aminopropyl)benzofuran (4-
APB) and 7-(2-aminopropyl)benzofuran (7-APB) are positional isomers of 5-APB and 6-APB. 
1-(2,3-Dihydrobenzofuran-5-yl)-N-methylpropan-2-amine (5-MAPDB) is a dihydrobenzofuran 
analogue of MDMA, and 5-(2-ethylaminopropyl)benzofuran (5-EAPB) is a benzofuran 
analogue of MDMA but with an N-ethyl group (Fig. 1). 
5-APB and 6-APB appeared on the drug market in 2010-2011 (Chan et al., 2013; 
Jebadurai et al., 2013; Stanczuk et al., 2013; Archer et al., 2014; Elliott et al., 2014; King, 
2014), with reports of intoxication (Chan et al., 2013; Greene, 2013; Jebadurai et al., 2013; 
Seetohul et al., 2013). 4-APB was first reported to the EMCDDA in 2010 (King, 2014) and is 
typically detected in products that are sold as 6-APB as byproduct (Stanczuk et al., 2013; 
Strano Rossi et al., 2014). Users report that the effects of 5-APB and 6-APB are comparable 
to MDMA but more intense (Greene, 2013; Jebadurai et al., 2013). Adverse effects include 
nausea, sympathomimetic stimulation, and agitation (Chan et al., 2013; Greene, 2013). 5-
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APDB and 6-APDB were first reported to the EMCDDA in 2012, and another three 
benzofurans, including 5-EAPB, were first reported in 2013 (King, 2014). Presently, no 
published studies have reported the psychotropic and toxic effects of these benzofurans, but 
5-APDB, 6-APDB, and 5-EAPB are being discussed in drug user forums (Bluelight, 2013a; 
Bluelight, 2013b; Drugs-Forum, 2013). Little is known about the pharmacology of 
benzofurans. 5-APB and 6-APB have been shown to inhibit the human dopamine (DA), 
noradrenaline (NA), and serotonin (5-hydroxytryptamine [5-HT]) transporters (DAT, NET, 
and SERT, respectively; (Iversen et al., 2013) and are agonists at the rat 5-HT2A receptor 
(Dawson et al., 2014) and human and rat 5-HT2B receptor (Iversen et al., 2013; Dawson et 
al., 2014). Additionally, fast cyclic voltammetry experiments in rat brain slices indicated that 
5-APB releases DA at high concentrations (Dawson et al., 2014). 5-APDB and 6-APDB also 
inhibited the monoamine transporters with greater affinity for the SERT over the DAT 
compared with MDA in crude rat synaptosome preparations (Monte et al., 1993). 
The benzodifurans 8-bromo-2,3,6,7-benzo-dihydro-difuran-ethylamine (2C-B-FLY) and 
1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminoprop-ane) (bromo-dragonFLY) are known 
as “fly” drugs because of their chemical structures (Fig. 1). A series of benzodifurans were 
originally synthesized to study 5-HT2A receptor function (Monte et al., 1997; Parker et al., 
1998; Chambers et al., 2001). The recreational use of 2C-B-FLY and bromo-dragonFLY 
began to be reported in 2007 (Andreasen et al., 2009; Greene, 2013; King, 2014), and there 
are case reports of severe agitation, hallucinations, seizures, and fatalities associated with 
bromo-dragonFLY (Andreasen et al., 2009; Wood et al., 2009; Nielsen et al., 2010). 2C-B-
FLY and bromo-dragonFLY are potent 5-HT2A agonists (Monte et al., 1996; Chambers et al., 
2001), but interactions with other monoamine receptors and their transporters have not been 
tested. 
Systematic evaluations of the pharmacological profiles of benzofurans are lacking. We 
determined the potencies of a series of benzofurans and the benzodifuran 2C-B-FLY to 
inhibit the DAT, NET, and SERT and tested transporter-mediated monoamine release in 
vitro. We also characterized the binding profiles at monoamine receptors and assessed 5-
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HT2A and 5-HT2B receptor activation. The 5-HT2A receptor mediates hallucinogenic effects 
(Nichols, 2004), and the 5-HT2B receptor has been implicated in drug-associated endocardial 
fibrosis (Roth, 2007). MDMA, MDA, β-keto-MDA, and methamphetamine were included as 
comparator substances. 
 
Methods 
Drugs 
 MDMA, MDA, β-keto-MDA, methamphetamine, and 2C-B-Fly were obtained from 
Lipomed (Arlesheim, Switzerland). 6-APB, 6-APDB, 5-APB, 5-APDB, 4-APB, 7-APB, and 5-
MAPDB were obtained from Cayman Chemicals (Ann Arbor, MI, USA). 5-EAPB was 
obtained from the Forensic Institute (Zurich, Switzerland). All of the drugs were used as 
racemic hydrochloride salts. Purity was at least 98% for all of the substances, with the 
exception of 2C-B-Fly, whose purity was approximately 95% as determined by HPLC. 
 
Monoamine uptake transport inhibition 
 Inhibition of the human NET, DAT, and SERT was assessed in human embryonic 
kidney (HEK) 293 cells that were stably transfected with the transporters as specified 
previously (Hysek et al., 2012c). Briefly, the cells were suspended in uptake buffer. We 
incubated the cells for 10 min with different concentrations of the test compounds and then 
added the corresponding [3H]monoamine (5 nM final concentration) at room temperature. 
After 10 min, we stopped uptake by separating the cells from the buffer using centrifugation 
through silicone oil (Hysek et al., 2012c). The centrifugation tubes were frozen in liquid 
nitrogen and cut to separate the cell pellet from the silicone oil and assay buffer layers. The 
cell pellet was then lysed. Scintillation fluid was added, and radioactivity was counted on a 
beta-counter. Nonspecific uptake was determined for each experiment in the presence of 10 
M fluoxetine for SERT cells, 10 M nisoxetine for NET cells, and 10 M mazindol for DAT 
cells and subtracted from the total counts to yield specific uptake (100%). DAT:SERT 
inhibition ratios were calculated as 1/DAT IC50:1/SERT IC50. Higher relative potency at the 
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DAT indicates a higher abuse potential, whereas relatively increased activity of the 5-HT 
system is linked to a reduction of abuse potential and more MDMA-like psychotropic effects 
(Wee et al., 2005). Stimulant amphetamines, such as methamphetamine, have a DAT:SERT 
inhibition ratio > 10, whereas MDMA and other substances with MDMA-like psychotropic 
effects have a DAT:SERT inhibition ratio close to 0.1 (Baumann et al., 2012; Simmler et al., 
2013; Simmler et al., 2014a; Simmler et al., 2014b). 
 
Transporter-mediated monoamine release 
 We studied the effects of a single high dose (100 µM) of the test compounds on 
transporter-mediated NE, 5-HT, and DA efflux in HEK 293 cells that overexpressed the 
respective human monoamine transporter as previously reported in detail (Simmler et al., 
2013). Briefly, adherent cells were incubated with the respective radiolabeled monoamine 
(10 nM [3H]NA and 10 μM unlabelled NA, 10 nM [3H]DA and 1 μM unlabelled DA, and 10 nM 
[3H]5-HT) for 20 min at 37°C. We then washed the cells twice with buffer and added 1 ml of 
buffer that contained the test compound (100 μM final concentration). We stopped [3H]5-HT 
and [3H]DA release after 15 min and [3H]NA release after 45 min by washing twice with ice-
cold buffer. We quantified the radioactivity that remained in the cells. Nonspecific “pseudo-
efflux,” which arises from nonspecific substrate release and subsequent reuptake inhibition 
(Scholze et al., 2000), was assessed for each experiment using the transporter inhibitors 
nisoxetine (NET cells), citalopram (SERT cells), and mazindol (DAT cells) at 10 µM as 
negative control conditions.  
 
Radioligand binding assays 
 The radioligand binding assays were performed as described previously (Hysek et 
al., 2012c; Simmler et al., 2013). Briefly, membrane preparations of HEK 293 cells 
(Invitrogen, Zug, Switzerland) that overexpress the respective transporters (Tatsumi et al., 
1997) or receptors (human genes, except rat and mouse genes for TAAR1; (Revel et al., 
2011) were incubated with the radiolabeled selective ligands at concentrations equal to Kd, 
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and ligand displacement by the compounds was measured. Specific binding of the 
radioligand to the target receptor was defined as the difference between the total binding 
and nonspecific binding determined in the presence of selected competitors in excess. The 
following radioligands and competitors, respectively, were used: N-methyl-[3H]-nisoxetine 
and indatraline (NET), [3H]citalopram and indatraline (SERT), [3H]WIN35,428 and indatraline 
(DAT), [3H]8-hydroxy-2-(di-n-propylamino)tetralin and indatraline (5-HT1A receptor), 
[3H]ketanserin and spiperone (5-HT2A receptor), [
3H]mesulergine and mianserin (5-HT2C 
receptor), [3H]prazosin and risperidone (1 adrenergic receptor), [
3H]rauwolscine and 
phentolamine (2 adrenergic receptor), [
3H]SCH 23390 and butaclamol (D1 receptor), 
[3H]spiperone and spiperone (D2 and D3 receptors), [
3H]pyrilamine and clozapine 
(histaminergic H1 receptor), and [
3H]RO5166017 and RO5166017 (TAAR1).  
 
Functional serotonin 5-HT2A and 5-HT2B activity 
 The 5-HT2B receptor functional assay was performed as described previously 
(Jensen et al., 2008). Briefly, human 5-HT2B receptor-expressing HEK 293 cells were 
incubated at 37°C in 96-well plates coated with poly-D-lysine. The growth medium was 
removed by snap inversion, and 100 µl of Fluo-4 solution (calcium indicator; Molecular 
Probes, Eugene, OR, USA) was added to each well. The plates were incubated for 45 min at 
31C. The Fluo-4 solution was removed by snap inversion, and 100 µl of Fluo-4 solution was 
added a second time. The cells were then incubated for another 45 min at 31C. 
Immediately before testing, the cells were washed with Hank’s Buffered Saline Solution 
(Gibco) and 20 mM HEPES (assay buffer; Gibco) using an EMBLA cell washer, and 100 µl 
assay buffer was added. The plate was placed in a fluorescence imaging plate reader 
(FLIPR), and 25 µl of the test substances diluted in assay buffer was added online. The 
increase in fluorescence was then measured. Efficacy (maximal activity) is expressed 
relative to the activity of 5-HT, which was used as a control set to 100%. 
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Cytotoxicity 
 To confirm cell integrity during the pharmacological assays, cytotoxicity was 
assessed using the ToxiLightTM bioassay (Lonza, Basel, Switzerland) according to the 
manufacturer’s instructions. The assay quantitatively measures the release of adenylate 
kinase from damaged cells providing a highly sensitive method for measuring cytolysis 
(Crouch et al., 1993; Hysek et al., 2012c; Felser et al., 2014). Cells grown in 96-well plates 
were exposed to the compounds at a high concentration of 100 μM. All test conditions 
contained dimethyl sulfoxide (DMSO) 0.1% (v:v) which is non-toxic and was also used as 
negative control. TritonTM X-100 (0.1%) lyses cells and was used as positive control. After 4 
h of incubation at 37C 10 μl of supernatant per well was removed and combined with 50 μl 
of ToxiLightTM reagent and luminescence recorded using a Tecan InfiniteTM 200 Pro (Tecan, 
Männedorf, Switzerland) plate reader.   
 
Statistical analyses  
The uptake transporter inhibition data were fit by non-linear regression to variable-slope 
sigmoidal dose-response curves, and IC50 values were calculated using Prism software 
(GraphPad, San Diego, CA, USA). Analysis of variance followed by the Holm-Sidak test was 
used to compare compound-induced release with the negative controls. Substances that 
induced significantly higher monoamine efflux compared with the negative control were 
considered monoamine releasers. IC50 values for radioligand binding were determined by 
calculating nonlinear regression curves for an one-site model using three to five independent 
10-point concentration-response curves for each compound. Ki (affinity) values, which 
correspond to the dissociation constants, were determined using the Cheng-Prusoff 
equation. EC50 values for the 5-HT2 receptor activation were derived from the concentration-
response curves using nonlinear regression. 
 
Results 
Monoamine uptake transporter inhibition 
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Uptake inhibition curves are depicted in Fig. 2, and the corresponding IC50 values and 
DAT:SERT inhibition ratios are listed in Table 1. All of the benzofurans inhibited the NET at 
submicromolar concentrations, similar to MDMA, MDA, and methamphetamine. All of the 
benzofurans were weak DAT inhibitors compared with methamphetamine and more similar 
to MDMA, which was also a weak DAT inhibitor. Only 5-APB, 6-APB, and 5-EAPB were 
more potent at the DAT compared with MDMA and MDA. In contrast, the 
dihydrobenzofurans 5-APDB, 6-APDB, and 5-MAPDB were inactive at the DAT (IC50 > 30 
μM). 5-APB, 5-APDB, 6-APB, and 5-EAPB inhibited the SERT at submicromolar 
concentrations and more potently than MDMA. 6-APDB and 5-MAPDB inhibited the SERT in 
the 1-3 micromolar concentration range, similar to MDMA. 4-APB and 7-APB exhibited low 
potency at the SERT, more similar to methamphetamine. The DAT:SERT inhibition ratio for 
all of the benzofurans was low, consistent with greater serotonergic vs. dopaminergic activity 
that is overall similar to MDMA. The dihydrobenzofurans (5-APDB, 6-APDB, and 5-MAPDB) 
and 5-APB exhibited the lowest DAT:SERT inhibition ratios (lower than MDMA). In contrast, 
4-APB and 7-APB exhibited the highest DAT:SERT inhibition ratios, consistent with their low 
potency at the SERT and showing a profile that is between MDMA and methamphetamine 
with regard to serotonergic vs. dopaminergic activity. In terms of structure-activity 
relationships, the dihydro-compounds 5-APDB and 6-APDB had similar noradrenergic and 
serotonergic activities compared with their analogues 5-APB and 6-APB but were markedly 
less potent at the DAT. The monoamine transporter inhibition potencies of the positional 
isomers 4-APB and 7-APB were reduced, particularly for the SERT, compared with their 
analogues 5-APB and 6-APB. Additionally, the oxygen in the para-position for 5-APB and 5-
APDB resulted in higher absolute and relative potency at the SERT compared with 6-APB 
and 6-APDB, respectively. Beta-keto-substitution in the β-keto-MDA vs. MDA structures 
increased dopaminergic vs. serotonergic activity. The benzodifuran 2C-B-FLY was inactive 
at all of the monoamine transporters (IC50 > 50 μM). 
 
Monoamine release 
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 At high concentrations, all of the benzofurans released at least one of the 
monoamines through the respective monoamine transporter, similar to the amphetamines 
(Fig. 3). In contrast, 2C-B-FLY was not a monoamine releaser. 
 
Binding affinities 
 The benzofurans interacted with the monoamine transporters but also with several 
monoamine receptors (Table 2 and 3). All of the benzofurans exhibited submicromolar 
affinity for TAAR1, except for 5-EAPB, which was inactive at mouse TAAR1. Benzofurans 
showed mostly higher potency at TAAR1 than the classic amphetamines. All of the 
benzomonofurans exhibited binding affinities for the 5-HT2A receptor in the micromolar range 
(0.8-3.4 μM). Functionally, most of them acted as low-potency partial agonists similar to 
MDMA and MDA but unlike methamphetamine. Most of the benzofurans were also partial 
agonists at the 5-HT2B receptor. In contrast MDMA and methamphetamine did not stimulate 
5-HT2B receptors. With the exception of 7-APB and 5-EAPB, the benzofurans exhibited 
submicromolar binding affinities at the 5-HT2C receptor. Binding potencies at the 5-HT1 
receptor varied among the different benzofurans. Only 7-APB showed submicromolar 
binding affinity. Potent binding to most of the assessed 5-HT receptor subtypes distinctly 
discriminated the benzofurans from the pharmacological profiles of their related 
amphetamines, which exhibited no or low 5-HT1A affinity and did not bind to 5-HT2B or 5-HT2C 
receptors except for MDA with a Ki value of 3 μM at 5-HT2C. Most of the benzofurans bound 
to α1- and α2-adrenergic receptors in the 3-12 μM and 0.1-6 μM ranges, respectively. There 
was no binding to DA receptors and only low-affinity binding to histamine H1 receptors (> 10 
μM for most of the drugs). The benzodifuran 2C-B-FLY did not bind to the monoamine 
transporters but interacted with all of the receptors tested in the present study and 
particularly exhibited high affinity for TAAR1 and all of the 5-HT2 receptors. Importantly, 2C-
B-FLY was a very potent agonist at the 5-HT2A receptor. 2C-B-FLY thus exhibited a 
pharmacological profile that was distinct from the mono-benzofurans and related 
amphetamines. 
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Cytotoxicity 
 None of the investigated compounds produced cytotoxicity, thus confirming cell 
integrity during the functional assays in this study. 
 
Discussion 
We determined the in vitro pharmacological profiles of new benzofurans that are 
recreationally abused compared with their well-known amphetamine analogues. The 
benzofurans blocked monoamine transporters and induced transporter-mediated 
monoamine release similarly to MDMA. More than MDMA and methamphetamine, the 
benzofurans also directly stimulated adrenergic and 5-HT receptors. The benzodifuran 2C-
B-FLY was a potent agonist at 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors, consistent with 
the reported hallucinogenic properties of 2C-B-FLY. 
 
Monoamine uptake transporter inhibition and monoamine release 
All of the benzofurans inhibited the NET at submicromolar concentrations, similar to MDMA, 
MDA, and methamphetamine. Noradrenaline mediates sympathomimetic stimulation (Hysek 
et al., 2011), and this finding predicts the cardiostimulant and psychostimulant properties of 
these benzofurans, similar to MDMA and methamphetamine. Unlike the relatively constant 
NET inhibition, the potencies of the benzofurans to inhibit the DAT and SERT notably varied, 
resulting in DAT:SERT inhibition ratios that ranged from 0.01 to 0.65. Specifically, the 
dihydrobenzofurans 5-APDB and 5-MAPDB exhibited the highest preference for the SERT 
vs. DAT (more selective than MDMA), followed by 5-APB, 6-APDB, and 5-EAPB, which 
exhibited a DAT:SERT inhibition ratio similar to MDMA. With DAT:SERT ratios of 0.46 and 
0.65, 4-APB and 7-APB were the benzofurans with the most dopaminergic profiles and were 
relatively more dopaminergic than MDMA. Stimulants like methamphetamine exhibit a 
DAT:SERT ratio > 10, whereas MDMA and other entactogens exhibit a DAT:SERT ratio of 
0.01-1 (Simmler et al., 2013; Liechti, 2014b; Simmler et al., 2014a; Simmler et al., 2014b). 
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Accordingly, based on their DAT:SERT inhibition ratios, all of the benzofurans can be 
expected to produce MDMA-like entactogenic subjective effects in humans. In contrast to 
the benzofurans, the benzodifuran 2C-B-FLY blocked monoamine transporters only at very 
high concentrations but had high affinity for 5-HT receptors. Thus, monoamine transporter 
inhibition is unlikely to contribute to the mechanism of action of 2C-B-FLY as is also the case 
for the structurally similar substance 2C-B and related compounds of the 2C phenethylamine 
series containing methoxy-groups at positions 2 and 5 of the benzene ring  (Acuna-Castillo 
et al., 2002; Hill et al., 2011; Eshleman et al., 2014). 
Only a few other studies determined the monoamine transporter inhibition profiles of 
some of the benzofurans. Consistent with our findings, 5-APDB and 6-APDB inhibited the 
SERT more potently than the DAT in rat synaptosomes (Monte et al., 1993). The oxygen in 
the para position in the 5-APDB and 5-APB structures enhanced the serotonergic vs. 
dopaminergic properties compared with 6-APDB and 6-APB, respectively, as shown in the 
present study and previously for 5-APDB vs. 6-APDB in rat synaptosomes (Monte et al., 
1993). Drug discrimination studies in rats showed that 5-APDB and 6-APDB substituted for 
MDMA-like serotonergic drugs but not the more dopaminergic stimulant amphetamine 
(Monte et al., 1993). These behavioural findings support our hypothesis that 5-APDB and 6-
APDB produce subjective effects that are similar to MDMA, and entactogenic effects have 
been reported by users (Bluelight, 2013a; Bluelight, 2013b; Drugs-Forum, 2013). The 
monoamine transporter inhibition profiles for 5-APB and 6-APB were determined in one 
previous study (Iversen et al., 2013). In contrast to our results, this study showed that 5-APB 
and 6-APB inhibited the DAT more potently than the SERT (Iversen et al., 2013). However, 
MDMA did not show the serotonergic preference that is typically reported by others 
(Rothman et al., 2001; Han et al., 2006; Hysek et al., 2012c; Simmler et al., 2013). 
Consistent with the present results, the inhibition profiles for 5-APB and 6-APB were similar 
to MDMA and unlike methamphetamine (Iversen et al., 2013). The reinforcing effects of 
benzofurans have not yet been studied in drug self-administration studies. There is a 
decrease in reinforcing potency and efficacy among monoamine releasing agents when 5-
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HT releasing potency is increased relative to DA (Wee et al., 2005). The relatively 
serotonergic in vitro properties of the benzofurans would indicate lower addictive properties 
(Wee et al., 2005; Liechti, 2014b), more similar to MDMA, which is not a strong reinforcer in 
self-administration studies (Lamb et al., 1987; Cole et al., 2003), than to methamphetamine. 
All of the benzofurans also released 5-HT, NA, and DA through their respective 
transporters, similar to their amphetamine analogues and other amphetamine derivatives 
(Simmler et al., 2013; Simmler et al., 2014a; Simmler et al., 2014b). Dopamine release has 
also been previously documented for 5-APB in voltammetric studies of rat brain slices 
(Dawson et al., 2014). In contrast to the benzofurans, 2C-B-FLY did not release 
monoamines. Our release assay was designed to qualitatively assess monoamine release 
because we used only one high concentration of the substances to induce transporter-
mediated monoamine efflux. Additional studies that include the assessment of transporter-
mediated ionic currents and in vivo microdialysis could be useful to further characterize and 
quantify monoamine release and its contribution to the mechanism of action of the 
benzofurans. 
 
Receptor binding profiles 
 The present study found several relevant high-potency interactions between the 
benzofurans and various monoamine receptors. 6-APB, 6-APDB, 4-APB, 7-APB, and 2C-B-
FLY all bound to α2A-adrenergic receptors, which are known to modulate NA release and 
sympathomimetic activity (Hysek et al., 2012a). As expected (Monte et al., 1996), 2C-B-FLY 
potently interacted with 5-HT2 receptors. Specifically, 2C-B-FLY potently bound to the 
human 5-HT2A receptor (Ki = 0.01 μM), consistent with the previously documented 
nanomolar affinity for rat cortical 5-HT2A receptors (Monte et al., 1996). Even higher-potency 
binding to 5-HT2A receptors has been shown for the benzodifuran bromo-dragonFLY in rat 
(Monte et al., 1996; Chambers et al., 2001) and human (Monte et al., 1996) 5-HT2A 
receptors. In the present study, 2C-B-FLY was also a very potent functional 5-HT2A receptor 
agonist. 2C-B-FLY resembles the structures of the 2C series phenethylamines, which are 
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also potent 5-HT2A receptor agonist (Nelson et al., 1999; Acuna-Castillo et al., 2002; Hansen 
et al., 2014). 
Consistent with the predicted lysergic acid diethylamide (LSD)-like properties of substances 
with high 5-HT2A receptor affinity, both 2C-B-FLY and bromo-dragonFLY completely 
substituted for LSD in drug discrimination studies (Monte et al., 1996). The affinity of 2C-B-
FLY for the 5-HT1A receptor was relatively low, which has also been shown for rat 5-HT1A 
receptors (Monte et al., 1996). The 5-HT2A receptor is thought to mediate the alterations in 
perception induced by hallucinogens (Vollenweider et al., 1998; Nelson et al., 1999; Nichols, 
2004) and therefore is likely the key target in the mechanism of action of benzodifuran 
hallucinogens. Interestingly, some of the benzofurans also exhibited micromolar affinity for 
the 5-HT2A receptor and were low-potency 5-HT2A receptor partial agonists similar to MDMA 
and MDA, but in contrast to methamphetamine. Binding to 5-HT2A receptors at micromolar 
concentrations has also been previously shown for 5-APB and 6-APB (Iversen et al., 2013). 
5-APB also constricted rat aorta via 5-HT2A agonist action (Dawson et al., 2014). Thus, some 
benzofurans could have hallucinogenic properties because of 5-HT2A receptor stimulation, in 
addition to their MDMA-like entactogenic subjective effects. Psychosis and hallucinations 
have been reported after the use of 6-APB (Chan et al., 2013; Greene, 2013). However, in 
drug discrimination studies, 5-APDB and 6-APDB did not substitute for LSD in rats (Monte et 
al., 1993), consistent with their lower binding affinity compared with 5-APB and 6-APB. In 
terms of clinical toxicity, the 5-HT2A agonist and possible α1-adrenergic agonist action could 
enhance the risk for vasoconstriction, hyperthermia, and hypertension. Both α1 and 5-HT2A 
receptors are implicated in substance-induced vasoconstriction (Blessing et al., 2003; 
Docherty et al., 2010; Dawson et al., 2014) and associated hypertension (Hysek et al., 2013) 
and hyperthermia (Liechti et al., 2000; Hysek et al., 2012b; Liechti, 2014a) in humans. In 
fact, hypertension, hyperpyrexia, and cases with severe limb ischemia have been reported 
after use of bromo-dragonFLY (Thorlacius et al., 2008; Wood et al., 2009; Nielsen et al., 
2010), a benzodifuran structurally similar to 2C-B-FLY. Direct agonist actions at the 5-HT2A 
receptor compared with an indirect action via 5-HT release can also be expected to result in 
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longer-lasting effects as described for serotonergic hallucinogens (Schmid et al., 2014) and 
compared with MDMA (Hysek et al., 2012c). 
In humans, MDMA is mainly inactivated by O-demethylation but also N-demethylated 
to the minor but active metabolite MDA (Hysek et al., 2013). Similarly, 5-MAPDB and 5-
EAPB are N-dealkylated (Welter et al., 2014) to 5-APDB and 5-APB, respectively. As shown 
in the present study, the N-dealkylated substances MDA, 5-APDB, and 5-APB activate 5-
HT2A and 5-HT2B receptors more potently and also more potently bind to 5-HT2C receptors 
than their parent compounds MDMA, 5-MAPDB, and 5-EAPB, respectively. Thus, the 
formation of active metabolites likely adds enhanced 5-HT2A and 5-HT2B-receptor-associated 
toxicity in these cases. 
2C-B-FLY and several of the benzofurans acted as partial agonists at the 5-HT2B 
receptor as previously shown for 5-APB (Iversen et al., 2013; Dawson et al., 2014) and 6 
APB (Iversen et al., 2013). In contrast, no such 5-HT2B agonist properties were observed for 
the classic amphetamines MDMA and methamphetamine in the present study. 5-HT2B 
receptors have been implicated in substance-induced heart valve fibrosis (Setola et al., 
2003; Bhattacharyya et al., 2009). 5-HT2B receptor activation by 2C-B-FLY, 5-APB, 6-APB, 
6-APDB, and 7-APB occurred at submicromolar concentrations that are likely present when 
these drugs are used by drug users to induce subjective effects. 
All of the benzofurans bound to TAAR1, many at even higher potency than MDMA or 
methamphetamine. MDMA and methamphetamine inhibit their own neurochemical and 
locomotor stimulant effects via TAAR1 activation (Di Cara et al., 2011). Similar TAAR1-
mediated “auto-inhibition” may therefore modulate the effects of benzofurans. In contrast, for 
cathinones (e.g., β-keto-amphetamines), more stimulant-like and addictive properties would 
be expected based on their lower affinity for TAAR1 compared with their amphetamine 
analogues (Simmler et al., 2013; Simmler et al., 2014a). 
In terms of structure-activity relationships, 3,4-substitution on the benzene ring 
(methylenedioxy-group in MDMA and MDA, furans, or dihydrofurans) strongly reduced the 
DAT/SERT inhibition ratio confirming previous studies (Nichols, 1994; Han et al., 2006; 
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Iversen et al., 2013; Simmler et al., 2013). Additionally, the DAT/SERT inhibition ratio 
depended on the position of the oxygen on the benzene ring and was lowest for compounds 
with the oxygen in the para-(4)-position and highest for those with the oxygen in the ortho-
(2)-position. This finding was consistent with the high serotonergic activity of other para-
substituted amphetamines (Nichols, 1994; Rickli et al., 2015). The dihydrobenzofurans (5-
APDB, 6-APDB, and 5-MAPDB) exhibited reduced monoamine transporter inhibition potency 
in particular at the DAT resulting in relatively more serotonergic properties compared to their 
furan analogues.  N-alkylation (MDMA, 5-MAPDB, 5-EAPB, methamphetamine) moderately 
reduced activity at 5-HT2A/B receptors and binding at 5-HT2C receptors. This has previously 
been shown for other phenethylamines for simple N-alkylation (e.g., methyl, ethyl) (Nelson et 
al., 1999). N-alkylation had no relevant effect on the interactions with the monoamine 
transporter as previously noted for related amphetamines (Nichols, 1994). 2,5-substitution 
on the benzene ring strongly increased activity at the 5-HT2 receptors and reduced 
interactions with the monoamine transporters as seen in 2C-B-FLY in the present study and 
many other 2,5-substituted phenethylamines (2C series) (Hill et al., 2011; Eshleman et al., 
2014). Transporter inhibition potency was also moderately reduced when the oxygen was in 
the ortho-(2)-position (similar to the 2 series) at the benzene ring as in 7-APB compared with 
5-APB, 6-APB, or 4-APB. Beta-keto-substitution increased dopaminergic vs. serotonergic 
activity extending previous similar findings (Simmler et al., 2013; Simmler et al., 2014a).   
 
 
Conclusions 
 Benzofurans are monoamine transporter blockers and monoamine releasers, similar 
to MDMA, but they also interact with serotonergic receptors. This mechanism of action 
predicts psychotropic and clinical toxicological effects that are similar to the entactogen 
MDMA but with additional hallucinogenic properties. The benzodifuran 2C-B-FLY is a potent 
hallucinogen, likely also associated with a risk for clinical complications related to 
vasoconstriction (e.g., ischemia and hypertension). Although structure-activity relationships 
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exist, the present study showed that structurally very similar compounds may exhibit distinct 
pharmacological profiles, illustrating the need for pharmacotoxicological profiling of each 
novel psychoactive substance. 
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Figure Legends 
 
Figure 1. Chemical structures of benzofurans and related amphetamines.  
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Figure 2. Monoamine uptake transporter inhibition. Concentration-response curves show 
the uptake inhibition of [3H]NA, [3H]DA, and [3H]5-HT in HEK 293 cells transfected with the 
respective monoamine transporter. The data are expressed as the mean ± SEM of 3-4 
independents experiments. Curves were fitted to the data with non-linear regression. The 
corresponding IC50 values are shown in Table 1. 
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Figure 3. Monoamine release. Monoamine release was induced by a high concentration of 
the compound (100 µM) after preloading the transporter-transfected cells with the respective 
radiolabeled monoamine. All of the benzofurans released NA, DA, and 5-HT similarly to 
methamphetamine and MDMA. In contrast, the benzodifuran 2CB-FLY was not a 
monoamine releaser. Transporter blockers induced nonspecific “pseudo-efflux” (horizontal 
dashed line, open bars), which arises from substrate that diffuses out of the cells and from 
subsequent reuptake inhibition. Compounds that produced significantly more monoamine 
efflux (*P < 0.05, *P < 0.01, ***P < 0.001) compared with the respective non-releasing 
uptake inhibitors (negative controls, open bars) were considered monoamine releasers. The 
data are expressed as the mean ± SEM of 3-4 independent experiments. 
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Table 1. Monoamine transporter inhibition.
NET DAT SERT DAT/SERT inhibition ratio
IC50 [µM] (95% CI) IC50 [µM] (95% CI) IC50 [µM] (95% CI) Ratio (95% CI)
Benzofurans
5-APB 0.16 (0.08-0.3) 6.1 (4-9) 0.29 (0.17-0.5) 0.05 (0.02-1.2)
5-APDB 0.29 (0.2-0.5) 49 (33-73) 0.58 (0.4-0.9) 0.01 (0.005-0.03)
6-APB 0.19 (0.1-0.3) 3.3 (2.4-4.5) 0.93 (0.7-1.3) 0.29 (0.16-0.54)
6-APDB 0.56 (0.4-0.8) 33 (25-43) 2.3 (1.4-3.9) 0.07 (0.03-0.16)
5-MAPDB 0.96 (0.5-1.7) 77 (62-96) 1.2 (0.7-2) 0.02 (0.01-0.03)
4-APB 0.24 (0.2-0.3) 12 (9-16) 5.5 (3.4-8.7) 0.46 (0.21-1.0)
7-APB 0.27 (0.2-0.3) 20 (16-26) 13 (9-18) 0.65 (0.35-1.1)
5-EAPB 0.56 (0.4-0.7) 4.9 (3-8) 0.72 (0.5-1.1) 0.15 (0.07-0.35)
Benzodifuran
2C-B-FLY 94 (72-124) 187 (161-217) 73 (58-92) 0.39 (0.27-0.57)
Related amphetamines
MDMA 0.36 (0.2-0.6) 16.7 (16.3-17) 2.4 (1.4-3.0) 0.14 (0.08-0.18)
MDA 0.42 (0.3-0.6) 20.5 (20.3-20.6) 4.9 (3.5-6.8) 0.24 (0.17-0.33)
beta-keto-MDA 1.6 (1.1-2.3) 14 (10-18) 21 (15-28) 1.5 (0.8-2.8)
Methamphetamine 0.14 (0.09-0.2) 0.87 (0.84-0.91) 13.6 (13.5-13.8) 15.6 (14.8-16.4)
Values are means of three to four independent experiments and 95% confidence intervals (CI). 
DAT/SERT inhibition ratio = 1/DAT IC50 : 1/SERT IC50.
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Table 2. Monoamine transporter and receptor binding affinities. 
NET DAT SERT a1A a2A D1 D2 D3 H1 TAAR1rat TAAR1mouse
Benzofurans
5-APB 3.1 ± 0.2 2.6 ± 0.3 3.2 ± 0.4 3.5 ± 0.5 2.9 ± 0.1 > 14 > 10 > 17 8.4 ± 0.8 0.04 ± 0.01 0.11 ± 0.01
5-APDB 28 ± 5 > 30 4.0 ± 0.3 11 ± 3 4.2 ± 0.5 > 14 > 10 > 17 21 ± 2 0.49 ± 0.05 0.77 ± 0.06
6-APB 1.8 ± 0.4 0.60 ± 0.05 12 ± 1 7.3 ± 3.4 0.38 ± 0.02 > 14 > 10 > 17 15 ± 2 0.05 ± 0.02 0.06 ± 0.02
6-APDB 18 ± 1 >30 23 ± 1 > 15 0.65 ± 0.07 > 14 > 10 > 17 > 25 1.0 ± 0.04 0.21 ± 0.04
5-MAPDB 26 ± 5 >30 6.3 ± 0.6 4.9 ± 1.5 6.4 ± 1.8 23 ± 3 > 10 > 17 4.9 ± 0.1 0.67 ± 0.09 3.5 ± 0.1
4-APB 3.9 ± 0.5 7.4 ± 0.6 7.7 ± 0.5 12 ± 3 0.87 ± 0.22 > 14 > 10 > 17 16 ± 1 0.11 ± 0.02 2.08 ± 0.14
7-APB 5.3 ± 0.1 14 ± 2 14 ± 1 9.6 ± 2.4 0.14 ± 0.02 > 14 8.2 ± 3.2 > 17 25 ± 5 0.07 ± 0.01 0.13 ± 0.02
5-EAPB 1.0 ± 0.3 0.34 ± 0.02 0.52 ± 0.03 3.3 ± 0.5 2.7 ± 0.7 16 ± 3 > 10 > 17 2.4 ± 0.4 0.81 ± 0.08 > 15
Benzodifuran
2C-B-FLY 17 ± 4 > 26 10 ± 3 11 ± 1 0.78 ± 0.3 1.4 ± 0.2 1.9 ± 0.3 6.8 ± 1.2 3.4 ± 0.5 0.03 ± 0.01 0.71 ± 0.23
Related amphetamines
MDMA
a 27 ± 9 8.4 ± 3.3 13 ± 2 > 5 15 ± 10 > 12 > 20 > 17 > 13 0.37 ± 0.12 2.4 ± 1.1
MDA 13 ± 3.7 > 26 5.6 ± 1.5 > 5 1.1 ± 0.1 > 12 > 20 > 17 > 13 0.25 ± 0.04 0.16 ± 0.01
beta-keto-MDA > 30 11 ± 2 >30 > 5 15 ± 2 > 12 > 20 > 17 > 13 4.8 ±  0.9 6.5 ±  2.8
Methamphetamine
a 3.0 ± 2.2 1.8 ± 0.7 25 ± 10 > 5 6.1 ± 1.6 > 12 > 20 > 17 > 13 0.35 ± 0.12 0.55 ± 0.24
Values are Ki  given as microM (mean ±SD); 
a
values are from Simmler et al. 2014a.
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Table 3. Serotonin receptor interactions.
5-HT1A 5-HT2C
receptor binding 
Ki (µM)
receptor binding 
Ki (µM)
activation potency 
EC50 (µM)
activation efficacy % 
maximum
activation potency 
EC50 (µM)
activation efficacy % 
maximum
receptor binding 
Ki (µM)
Benzofurans
5-APB 3.3 ± 0.2 0.84 ± 0.27 6.3 ±  2.1 54 ± 35 0.28 ±  0.12 61 ±  17 0.88 ± 0.33
5-APDB 20 ± 4 3.4 ± 1.0 11 ± 2 24 ± 17 1.2 ±  0.6 50 ± 21 0.06 ± 0.02
6-APB 1.5 ± 0.2 0.97 ± 0.23 5.9 ± 1.8 43 ± 23 0.14 ±  0.06 70 ± 9 0.27 ± 0.05
6-APDB 9.2 ± 1.5 2.0 ± 1.0 5.9 ± 1.1 62 ± 36 0.12 ± 0.03 66 ± 17 0.06 ± 0.02
5-MAPDB 26 ± 6 4.8 ± 2.1 > 20 0 > 20 0 0.10 ± 0.02
4-APB 1.2 ± 0.1 0.96 ± 0.17 13 ±  2 30 ± 9 1.0 ± 0.5 38 ± 16 0.06 ± 0.02
7-APB 0.28 ± 0.05 0.91 ± 0.20 5.7 ± 2.0 43 ± 21 0.28 ± 0.52 52 ± 17 3.3 ± 0.3
5-EAPB 3.1 ± 0.6 2.7 ± 1.5 7.6 ± 3.2 29 ± 7 > 20 0 4.6 ± 1.3 
Benzodifuran
2C-B-FLY 0.35 ± 0.04 0.011 ± 0.002 0.0015 ± 0.0002 82 ± 12 0.040 ± 0.036 56 ± 3 0.012 ± 0.004  
related amphetamines
MDMA 12 ± 0.8
a 6.3 ± 2.4 6.1 ± 0.3 55 ± 9 > 20 0 > 13
a
MDA 4.9 ± 0.9 3.3 ± 0.8 0.63 ± 0.24 77 ± 16 0.85 ± 0.11 52 ± 12 3.0 ± 0.9 
beta-keto-MDA > 17 > 13 > 20 0 > 20 0 > 13
Methamphetamine 8.1 ± 0.7
a > 13 > 20 0 > 20 0 > 13
a
 Values are Ki given as microM (mean±SD). 
a
values are from Simmler et al. 2014a and were included for comparison.
5-HT2A 5-HT2B 
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Table 4. Structure-activity relationships
structure present in not present in pharmacolocial (clinical) activity
MDMA, 5-MAPDB, 5-EAPB methamphetamine
MDA, 5-APB, 6-APB, 5-APDB, 6-
APDB, 7-APB, β-keto-MDA
a
amphetamine 
oxygen in para-(4)-position 5-APB, 5-APDB, 5-MAPDB
7-APB, 4-APB, 6-APB, 6-
APDB
reduced DAT/SERT ihibition ratio (more serotonergic)
dihydrobenzofuran 5-APDB, 6-APDB, 5-MAPDB
5-APB, 6-APB, 4-APB, 7-
APB
reduced DAT/SERT ihibition ratio (more serotonergic)
N-alkyl group MDMA, 5-EAPB, 5-MAPDB MDA, 5-APB, 5-APDB
reduced 5-HT2A/B receptor activation and 5-HT2C 
receptor binding potency (less hallucinogenic)
2,5-oxy-substitution on benzene 
ring
2C-B-FLY all other compounds
strongly increased 5-HT2A/B receptor activation, 
strongly increased 5-HT2C receptor binding potency 
(more hallucinogenic)
β-keto group β-keto MDA MDA a,bincreased DAT/SERT ratio (more dopaminergic)
a
Simmler et al 2013, 
b
Simmler et al. 2014a
3,4-substitution on benzene ring 
(methylenedioxy or furan)
reduced DAT/SERT inhibition ratio, 
a
increased 
potency to release 5-HT, 
a
reduced potency to release 
DA (more entactogenic, less stimulant)
 
